Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04732104
Other study ID # UWahid
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date July 20, 2018
Est. completion date August 14, 2020

Study information

Verified date January 2021
Source Dow University of Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Different anesthetic techniques are used for achieving pulpal anesthesia of maxillary teeth. Recently tetracaine and oxymetazoline were used as local anesthetic agents in the form of an intranasal spray to achieve pulpal anesthesia of maxillary teeth. However tetracaine has its share of demerits, therefore we in our study have used lidocaine with xylometazoline in the form of an intranasal spray to achieve local anesthesia of maxillary anterior and premolar teeth for restorative procedures. The objective of the study was to evaluate the efficacy of 4% lidocaine and 0.1% xylometazoline intranasal spray solution as compared to injectable 2% lidocaine with 1:100,000 epinephrine solution in anesthetizing maxillary anterior & premolar teeth for dental restorative procedures. METHODS: A total of 60 patients were enrolled in the study. Consecutive sampling was done for the study participants who met the inclusion criteria. 30 patients were randomized each to lidocaine/Xylometazoline or control local anesthesia group. Group A participants received 4% Lidocaine and 0.1% Xylometazoline solution as intranasal spray while Group B participants received injectable local anesthesia. Group 'A' participants received two doses of intranasal spray anesthesia four minutes apart. Local anesthesia was then assessed by probing soft tissues adjacent to the tooth and reading was taken on the Visual Analog Scale. If the reading was '0' the cavity preparation was performed. If the VAS reading was more than '0' a third dose of intranasal spray anesthesia was delivered. Local anesthesia was again assessed after ten minutes. If profound local anesthesia was still not achieved the case was labeled as failure of intranasal spray anesthesia and local anesthesia was achieved by conventional infiltration anesthesia. For Group B participants, local anesthesia was achieved by means of conventional infiltration anesthesia. Data were recorded on a designed proforma. Chi-square test and Fischer exact test were applied to see the difference of efficacy among the two groups and any influence of variables (age group, gender, tooth location, cavity classification, ICDAS score or the number of sprays required to produce local anesthesia) on the efficacy.


Description:

Different anesthetic techniques are used for achieving pulpal anesthesia of maxillary teeth. The most commonly used technique is the infiltration anesthesia that currently is the gold standard. However, infiltration uses a dental needle that is associated with its de merits also. This led to the discovery of novel methods to anesthetize teeth with smaller diameter needles or computerized delivery of local anesthesia. Recently tetracaine and oxymetazoline were used as local anesthetic agents in the form of an intranasal spray to achieve pulpal anesthesia of maxillary teeth. However tetracaine has its share of demerits, therefore we in our study have used lidocaine with xylometazoline in the form of an intranasal spray to achieve local anesthesia of maxillary anterior and premolar teeth for restorative procedures. OBJECTIVES: The objective of the study was to evaluate the efficacy of 4% lidocaine and 0.1% xylometazoline intranasal spray solution as compared to injectable 2% lidocaine with 1:100,000 epinephrine solution in anesthetizing maxillary anterior & premolar teeth for dental restorative procedures. METHODS: This open label randomized controlled trial was performed at the Department of Operative Dentistry, Dr.Ishrat Ul Ebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences Karachi between July 2018 and June 2020. A total of 60 patients were enrolled in the study. Consecutive sampling was done for the study participants who met the inclusion criteria. 30 patients were randomized each to lidocaine/Xylometazoline or control local anesthesia group. Group A participants received 4% Lidocaine and 0.1% Xylometazoline solution as intranasal spray while Group B participants received injectable local anesthesia. Group 'A' participants received two doses of intranasal spray anesthesia four minutes apart. Local anesthesia was then assessed by probing soft tissues adjacent to the tooth and reading was taken on the Visual Analog Scale. If the reading was '0' the cavity preparation was performed. If the VAS reading was more than '0' a third dose of intranasal spray anesthesia was delivered. Local anesthesia was again assessed after ten minutes. If profound local anesthesia was still not achieved the case was labeled as failure of intranasal spray anesthesia and local anesthesia was achieved by conventional infiltration anesthesia. For Group B participants, local anesthesia was achieved by means of conventional infiltration anesthesia. Data were recorded on a designed proforma. SPSS v16 was used to analyze the data with level of significance set at p<0.05. Demographic data were analyzed upon the basis of frequency and percentages. Chi-square test and Fischer exact test were applied to see the difference of efficacy among the two groups and any influence of variables (age group, gender, tooth location, cavity classification, ICDAS score or the number of sprays required to produce local anesthesia) on the efficacy.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 14, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility INCLUSION CRITERIA - Adults aged 18-40 years, - Patients having a vital maxillary premolar, canine or incisor. - Patients having Class 1,2,3,4 or 5 restorations (G.V. Black).95 - Patients having heart rate between 55 and 100 beats per min. - Patients with a seated Systolic blood pressure between 95 and 150 mm Hg and diastolic blood pressure between 60 and 100 mm of Hg. (Although short-term use of topical alpha-2 agonists like xylometazoline has no systemic toxicity and are available as over the counter drugs but long-term abuse has been reported to cause systemic vasoconstriction and cardiovascular complications like hypertensive crisis therefore the cut off limit has been selected for blood pressure). - Teeth with no radiographic evidence of pulpal or periapical pathosis. - Patients having ICDAS caries detection score of 4, 5 or 6. - Patients who fulfilled alcohol sniff test criterion. EXCLUSION CRITERIA - Patients with Upper respiratory tract infection. - Patients with Uncontrolled thyroid disease. - Patients having a known allergy to any of the components used in the solution. - Pregnant or breast feeding patients. - Those patients having 5 or more nosebleeds per month. - Patients who received any local anesthetic/analgesic within 24 hours of study drug administration.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine topical
intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
Lidocaine Hydrochloride
injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth

Locations

Country Name City State
Pakistan Dow University of Health Sciences Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Dow University of Health Sciences

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Achievement of local anesthesia local anesthesia will be assessed with the help of Visual Analog Scale. VAS score must be '0' before cavity preparation must begin First reading on VAS will be taken after administering 2 intranasal sprays i.e. 14 minutes after administration of the first spray
Primary Achievement of local anesthesia local anesthesia will be assessed with the help of Visual Analog Scale. VAS score must be '0' before cavity preparation must begin If needed, second reading on VAS will be taken after administering 3 intranasal sprays i.e. 24 minutes after administration of the first spray
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04549012 - Determination of Blood Loss After CS Early Phase 1
Active, not recruiting NCT06114758 - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Not yet recruiting NCT04562493 - Comparative Effect of Transforaminal Injection of Magnesium Sulphate Versus Ozone Therapy on Oxidative Stress Biomarkers in Lumbar Disc Related Radicular Pain N/A
Completed NCT04762147 - Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy Phase 3
Not yet recruiting NCT05510986 - The Effect of Oxycodone Hydrochloride on CRBD After TURBT Under General Anesthesia N/A
Completed NCT06432309 - Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease N/A
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT05968885 - Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Phase 4
Recruiting NCT05595044 - Effect of Vitamin D Therapy in Autism Spectrum Disorder Phase 1
Not yet recruiting NCT06100510 - PFA 100 Evaluation and Reference Interval HOACNY Phase 4
Completed NCT05060913 - Emla Cream Versus Benzocaine on Analgesia Early Phase 1
Not yet recruiting NCT05293119 - Role of Tofacitinib in Vitiligo Patients Early Phase 1
Not yet recruiting NCT06414018 - Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment N/A
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Not yet recruiting NCT06290219 - The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction Phase 3
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT05482451 - Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer Early Phase 1
Not yet recruiting NCT04892212 - Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Phase 2/Phase 3